ARQT vs INCY: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

Reading it: INCY is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. ARQT and INCY share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined ARQT and INCY exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Arcutis Biotherapeutics is a commercial-stage biopharmaceutical company focused on medical dermatology. Its business is built around ZORYVE, a topical formulation of roflumilast that inhibits phosphodiesterase type 4 (PDE4), an anti-inflammatory target long used in dermatology. ZORYVE is sold as a cream 0.3% for plaque psoriasis, a foam 0.3% for seborrheic dermatitis, and cream formulations (0.15% and 0.05%) for atopic dermatitis spanning adults down to young children. The pitch to dermatologists is a steroid-free, once-daily topical with a clean tolerability profile that can be used on sensitive and intertriginous skin, and the company markets it as the leading branded topical across those three inflammatory skin conditions combined.

Full ARQT guide

Incyte Corporation is a Wilmington, Delaware based biopharmaceutical company that discovers, develops, and commercializes drugs in oncology, hematology, and dermatology. Its flagship product is Jakafi (ruxolitinib), an oral JAK inhibitor approved for myelofibrosis, polycythemia vera, and graft-versus-host disease, which still generates the largest share of company revenue (roughly $758 million in Q1 2026, up about 7%). Beyond Jakafi, Incyte sells the topical cream Opzelura (ruxolitinib) for atopic dermatitis and vitiligo, plus a widening hematology and oncology lineup including Monjuvi/Minjuvi, Niktimvo, and Zynyz, and it funds a broad clinical pipeline of oncology and immunology candidates.

Full INCY guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• ARQT drivers: Multi-indication ZORYVE expansion; Revenue growth reaching profitability.
• INCY drivers: Jakafi franchise still growing near-term; Non-Jakafi revenue diversification.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: The dominant risk is single-product concentration: nearly all revenue depends on ZORYVE, so any slowdown in prescriptions, an unfavorable payer or pricing shift, a safety signal, or eventual generic and patent challenges would hit the whole company. For INCY, the dominant risk is revenue concentration: Jakafi still drives the majority of sales and faces US loss of exclusivity in December 2028, after which generic ruxolitinib is expected to erode the franchise.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick ARQT if you believe its drivers more; INCY if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the ARQT and INCY guides.

ARQT. As of MAY 2026, Arcutis trades as a high-growth, single-franchise dermatology name rather than a stable earner, so its valuation leans on ZORYVE's revenue trajectory and the durability of its early profitability. With a market cap near $3 billion against roughly $372 million of 2025 sales, the price-to-sales multiple reflects growth expectations, and the stock is sensitive to any change in prescription momentum or guidance. Because full-year GAAP profitability is not yet consistent, trailing P/E is not a meaningful anchor.

INCY. Incyte trades at a modest multiple for a profitable biopharma, with a forward P/E around 12x reflecting strong recent earnings growth but investor caution about the 2028 Jakafi cliff. The trailing P/E collapsed from triple digits in early 2025 to the mid-teens through 2026 as earnings normalized. Figures are approximate as of mid-2026 and move with reported results and the share price.

Headline figures (approximate, MAY 2026): ARQT shows zoryve net sales (fy2025) ~$372 million (+123% YoY), 2026 revenue guidance ~$480-495 million, q4 2025 revenue ~$128 million (+84% YoY), q4 2025 net income ~$17 million (first profitable quarter); INCY shows revenue (ttm) ~$4.8B, q1 2026 revenue ~$1.27B (up ~21% YoY), jakafi q1 2026 net sales ~$758M, cash & marketable securities ~$4.0B.

ARQT and INCY are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined ARQT and INCY exposure against your real portfolio. It is not an investment adviser.